NCT07290088 2025-12-23
PRL3-zumab
Intra-IMMUSG Pte Ltd
Phase 2/3 Recruiting
Clinical Trials
7 trialsNCT07092748 2025-07-30
A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 1 Recruiting
NCT06710158 2025-07-29
Study of SC-102 in Patients With Advanced Solid Tumors
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1 Recruiting
NCT02694822 2025-03-17
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
Agenus Inc.
Phase 1/2 Completed
NCT03956680 2025-02-19
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
Bristol-Myers Squibb
Phase 1 Completed
NCT03254732 2022-04-27
Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers
Polaris Group
Phase 1 Terminated
NCT01019941 2010-12-16
126ASC08Q
Chong Kun Dang Pharmaceutical
Phase 1 Completed